Current Indications for PD-1/PD-L1 Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Head and neck cancer and skull base surgeon Nyall London discusses three key immunotherapy clinical trials including KEYNOTE-012, Checkmate 141 and KEYNOTE-048 that have contributed to Food and Drug Administration approval for nivolumab and pembrolizumab, which are PD-1 inhibitors, for recurrent head and neck squamous cell carcinoma.

Created by

Johns Hopkins Medicine

Related Presenters

Nyall London, MD, PhD

Nyall London, MD, PhD

Assistant Professor of Otolaryngology - Head and Neck Surgery
Assistant Professor of Neurosurgery

Dr. London maintains a clinical practice focused on inflammatory sinonasal disease, skull base disorders, and malignancies of the skull base, sinonasal cavity, and oral cavity.

View full profile